Products Applications & Insights Knowledge & Support About QIAGEN My QIAGEN Quick Order Cart Site Search Key Figures Overview At a glance Stock Information Financial Reports & SEC Filings Corporate Governance Compliance & Sustainability Events & Presentations IR Contacts Investor Relations At a glance Key Figures Years ended December 31 $1,000 except per share data 2020 2019 2018 2017 2016 Result Net sales 1,870,346 1,526,424 1,501,848 1,417,536 1,337,991 Operating income (loss) 386,431 (26,136) 266,581 153,419 98,827 Net income (loss)1 359,188 (41,455) 190,380 40,394 80,404 Basic earnings (loss) per share (EPS)1 1.57 (0.18) 0.84 0.18 0.34 Diluted earnings (loss) per share (EPS)1 1.53 (0.18) 0.82 0.17 0.34 Number of shares (in thousands) Common shares used to compute basic earnings per share2 228,427 226,777 226,640 228,074 234,800 Common shares used to compute diluted earnings per share3 234,214 226,777 233,456 233,009 238,993 Cash flow Cash flow from operations 457,806 330,843 359,496 286,779 341,602 Capital expenditures for property, plant and equipment 132,787 117,950 109,773 90,081 74,536 Free cash flow4 325,019 212,893 249,723 196,698 267,066 As of December 31 Balance sheet Total assets 5,912,530 5,235,616 5,748,332 5,038,516 4,308,194 Cash, cash equivalents and restricted cash 597,984 629,390 1,159,079 657,714 439,180 Total long-term liabilities, including current portion 2,542,144 2,032,924 2,644,373 2,174,087 1,393,668 Total equity 2,797,839 2,536,591 2,634,970 2,540,996 2,607,096 Please visit Financial Reports for more information. 1Attributable to the owners of QIAGEN N.V. 2Weighted average number of common shares used to compute basic earnings per common share 3Weighted average number of common shares used to compute diluted earnings per common share 4Free cash flow is calculated from cash provided by operations reduced by purchases of property, plant and equipment IR Contacts John Gilardi Vice President Head of Corporate Communications and Investor Relations Germany +49 2103 29 11711 U.S. +1 240 686 2222 The Netherlands +31 773 55 66 66 john.gilardi@qiagen.com Download VCARD Phoebe Loh Senior Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com Download VCARD Alexandra Koenig Investor Relations Coordinator +49 2103 29 11709 alexandra.koenig@qiagen.com Download VCARD Email Alerts Email Address SIGN UP Press Releases Events Presentations SEC-Filings End of Day Stock Quote Unsubscribe Follow Us linkedin open in new window facebook open in new window twitter open in new window youtube open in new window linkedin open in new window Contact Us call back mail BACK TO TOP This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Sample to Insight © QIAGEN 2013-21. All rights reserved Privacy Policy Trademarks & Disclaimers Accessibility Powered By Q4 Inc. 5.56.0.1 (opens in new window)